Skip to main content


Established in 2009, Mérieux Developpement invests in growth equity and venture capital within the healthcare and nutrition sectors.

  • 2017 Acquisition

    Acquisition of Xeris & Ivantis

    • Acquisition by Mérieux Participations II (MP II) of a minority stake in Xeris Pharmaceuticals Inc. : biopharmaceutical company developing injectable therapeutics for  multiple indications including diabetes
    • Acquisition by MP II of a minority stake in Ivantis Inc., a company dedicated to the development of new and innovative solutions for glaucoma

  • 2016 Acquisition

    Acquisitions by Mérieux Développement

    In June 2016, Mérieux Développement via Mérieux Participations II (MP II) acquired a minority stake for
    EUR 22 million in Novacap, an international player in the chemical field. MP II also acquired, in November 2016, a minority stake for a total amount of EUR 15 million in Le Noble Age (LNA), active in the healthcare sector.

  • 2014 Acquisition

    Commitment of EUR 75 million to Mérieux Développement

    In the fourth quarter of 2014, commitment by Sienna Capital of EUR 75 million to Mérieux Développement’s investment companies, vehicles specialised in growth and venture capital investments in the healthcare sector.